Quarterly ResultMay 12, 2026, 04:07 PM
Bolt Biotherapeutics BDC-4182 Data 3Q 2026; Cash $23.9M into 2027
AI Summary
Bolt Biotherapeutics reported a net loss of $7.2 million for the first quarter ended March 31, 2026, with R&D expenses decreasing to $4.8 million and G&A expenses to $2.8 million due to restructuring. The company announced that initial clinical data from its BDC-4182 Phase 1/2 study for gastric and gastroesophageal cancer is expected in the third quarter of 2026. Bolt's cash balance of $23.9 million as of March 31, 2026, is projected to fund operations into 2027, including the completion of the BDC-4182 dose escalation.
Key Highlights
- Initial clinical data from BDC-4182 Phase 1/2 study expected in 3Q 2026.
- Cash, cash equivalents, and marketable securities were $23.9 million as of March 31, 2026.
- Cash on hand is anticipated to fund operations into 2027.
- Q1 2026 net loss was $7.2 million, compared to $11.0 million in Q1 2025.
- Q1 2026 R&D expenses decreased to $4.8 million from $9.5 million in Q1 2025.
- Q1 2026 G&A expenses decreased to $2.8 million from $3.8 million in Q1 2025.
- Q1 2026 collaboration revenue was $26,000, down from $1.2 million in Q1 2025.